 Kathleen Torkko
Concepts (282)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 18 | 2021 | 925 | 1.720 |
Why?
| | Vitamin D | 4 | 2020 | 341 | 0.860 |
Why?
| | Prostate | 4 | 2015 | 157 | 0.750 |
Why?
| | Biopsy | 7 | 2019 | 1045 | 0.590 |
Why?
| | Adenocarcinoma | 4 | 2020 | 801 | 0.590 |
Why?
| | Breast Neoplasms | 9 | 2024 | 1870 | 0.480 |
Why?
| | Prostatic Hyperplasia | 1 | 2015 | 38 | 0.480 |
Why?
| | Receptors, Androgen | 4 | 2021 | 131 | 0.450 |
Why?
| | B7-1 Antigen | 6 | 2010 | 54 | 0.440 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 1893 | 0.410 |
Why?
| | Biomarkers, Tumor | 9 | 2019 | 1054 | 0.350 |
Why?
| | Estrogen Receptor alpha | 3 | 2020 | 121 | 0.330 |
Why?
| | 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2008 | 9 | 0.310 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2102 | 0.310 |
Why?
| | Receptors, Calcitriol | 1 | 2008 | 53 | 0.300 |
Why?
| | Polymorphism, Genetic | 2 | 2008 | 612 | 0.300 |
Why?
| | Phenylthiohydantoin | 3 | 2021 | 40 | 0.300 |
Why?
| | Tamoxifen | 4 | 2016 | 192 | 0.290 |
Why?
| | Inflammation | 2 | 2015 | 2485 | 0.260 |
Why?
| | Immunohistochemistry | 11 | 2019 | 1635 | 0.260 |
Why?
| | Biomarkers | 2 | 2015 | 3418 | 0.260 |
Why?
| | Receptors, Estrogen | 5 | 2017 | 372 | 0.240 |
Why?
| | Aged, 80 and over | 11 | 2020 | 6363 | 0.230 |
Why?
| | Triple Negative Breast Neoplasms | 2 | 2017 | 158 | 0.230 |
Why?
| | Endometrium | 4 | 2008 | 60 | 0.230 |
Why?
| | Aged | 22 | 2020 | 19120 | 0.230 |
Why?
| | Middle Aged | 25 | 2020 | 26801 | 0.220 |
Why?
| | Bone Morphogenetic Proteins | 1 | 2024 | 132 | 0.210 |
Why?
| | Ovarian Neoplasms | 4 | 2010 | 388 | 0.210 |
Why?
| | 5-alpha Reductase Inhibitors | 2 | 2020 | 16 | 0.210 |
Why?
| | Finasteride | 2 | 2020 | 35 | 0.200 |
Why?
| | Bone Neoplasms | 1 | 2024 | 194 | 0.190 |
Why?
| | Cell Line, Tumor | 9 | 2021 | 2725 | 0.180 |
Why?
| | MAP Kinase Kinase Kinases | 1 | 2021 | 68 | 0.180 |
Why?
| | Risk | 3 | 2020 | 815 | 0.180 |
Why?
| | Macrophages | 3 | 2024 | 1266 | 0.180 |
Why?
| | 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2020 | 16 | 0.170 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 3 | 2018 | 114 | 0.170 |
Why?
| | Medical History Taking | 1 | 2000 | 114 | 0.170 |
Why?
| | DNA Helicases | 1 | 2021 | 134 | 0.170 |
Why?
| | Humans | 45 | 2024 | 114925 | 0.170 |
Why?
| | Chlamydia Infections | 1 | 2000 | 65 | 0.170 |
Why?
| | Disease Progression | 5 | 2018 | 2392 | 0.170 |
Why?
| | Antineoplastic Agents, Hormonal | 3 | 2014 | 138 | 0.170 |
Why?
| | Neoplasm Proteins | 2 | 2016 | 385 | 0.170 |
Why?
| | RNA Interference | 1 | 2021 | 437 | 0.160 |
Why?
| | Male | 24 | 2021 | 55655 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2021 | 1148 | 0.160 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2018 | 692 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 642 | 0.160 |
Why?
| | Metabolic Networks and Pathways | 1 | 2020 | 168 | 0.160 |
Why?
| | Carcinoma, Endometrioid | 3 | 2008 | 46 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2020 | 3008 | 0.160 |
Why?
| | Euterpe | 1 | 2018 | 6 | 0.160 |
Why?
| | Physicians, Family | 1 | 2000 | 201 | 0.160 |
Why?
| | Tryptophan Oxygenase | 1 | 2018 | 22 | 0.160 |
Why?
| | Uterine Cervical Dysplasia | 2 | 2010 | 42 | 0.150 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2021 | 863 | 0.150 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2011 | 77 | 0.150 |
Why?
| | Androgen Receptor Antagonists | 2 | 2017 | 30 | 0.150 |
Why?
| | Exosomes | 1 | 2019 | 91 | 0.150 |
Why?
| | Carcinosarcoma | 1 | 2017 | 17 | 0.150 |
Why?
| | Tryptophan | 1 | 2018 | 135 | 0.150 |
Why?
| | Insulin-Like Growth Factor II | 1 | 2017 | 23 | 0.140 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 2017 | 38 | 0.140 |
Why?
| | Motor Neurons | 2 | 1990 | 212 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2017 | 73 | 0.140 |
Why?
| | Precancerous Conditions | 2 | 2010 | 158 | 0.140 |
Why?
| | Observer Variation | 1 | 2017 | 297 | 0.140 |
Why?
| | Plant Extracts | 1 | 2018 | 155 | 0.140 |
Why?
| | Microfilament Proteins | 1 | 2017 | 127 | 0.140 |
Why?
| | Calcitriol | 1 | 2016 | 53 | 0.130 |
Why?
| | Antigens, CD | 2 | 2015 | 443 | 0.130 |
Why?
| | Endometrial Neoplasms | 2 | 2008 | 141 | 0.130 |
Why?
| | Phenotype | 2 | 2024 | 2817 | 0.130 |
Why?
| | Proteome | 1 | 2019 | 339 | 0.120 |
Why?
| | Maryland | 1 | 2015 | 37 | 0.120 |
Why?
| | Protein Tyrosine Phosphatases | 1 | 2016 | 147 | 0.120 |
Why?
| | CD8 Antigens | 1 | 2015 | 69 | 0.120 |
Why?
| | Leukocyte Common Antigens | 1 | 2015 | 76 | 0.120 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2015 | 54 | 0.120 |
Why?
| | Receptor, ErbB-2 | 1 | 2017 | 301 | 0.120 |
Why?
| | Genotype | 1 | 2020 | 1775 | 0.120 |
Why?
| | CD4 Antigens | 1 | 2015 | 124 | 0.120 |
Why?
| | Prostatitis | 1 | 2014 | 18 | 0.120 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2020 | 1215 | 0.120 |
Why?
| | Watchful Waiting | 1 | 2015 | 56 | 0.120 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2014 | 33 | 0.120 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2017 | 359 | 0.120 |
Why?
| | DNA-Binding Proteins | 1 | 2021 | 1317 | 0.120 |
Why?
| | Prognosis | 4 | 2017 | 3344 | 0.110 |
Why?
| | Prostatic Intraepithelial Neoplasia | 1 | 2013 | 12 | 0.110 |
Why?
| | Carrier Proteins | 1 | 2017 | 696 | 0.110 |
Why?
| | V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 6 | 2010 | 10 | 0.110 |
Why?
| | Androgen Antagonists | 1 | 2014 | 70 | 0.110 |
Why?
| | Endometrial Hyperplasia | 3 | 2008 | 10 | 0.110 |
Why?
| | Proteomics | 1 | 2019 | 844 | 0.110 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2010 | 58 | 0.110 |
Why?
| | Chromatin | 1 | 2016 | 428 | 0.110 |
Why?
| | Hindlimb | 2 | 1990 | 130 | 0.100 |
Why?
| | Nitriles | 3 | 2021 | 151 | 0.100 |
Why?
| | Benzamides | 3 | 2021 | 169 | 0.100 |
Why?
| | Apoptosis | 5 | 2017 | 2371 | 0.100 |
Why?
| | Muscle Denervation | 2 | 1990 | 9 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2000 | 1177 | 0.100 |
Why?
| | Female | 23 | 2024 | 59571 | 0.100 |
Why?
| | Nephrectomy | 1 | 2013 | 149 | 0.100 |
Why?
| | Receptors, Transferrin | 1 | 2011 | 22 | 0.100 |
Why?
| | Nerve Regeneration | 2 | 1990 | 50 | 0.100 |
Why?
| | Neoplasm Staging | 6 | 2017 | 1180 | 0.100 |
Why?
| | Imaging, Three-Dimensional | 2 | 2005 | 517 | 0.100 |
Why?
| | Patient Selection | 1 | 2015 | 642 | 0.090 |
Why?
| | NF-kappa B | 1 | 2014 | 637 | 0.090 |
Why?
| | Transcription Factors | 2 | 2008 | 1530 | 0.090 |
Why?
| | Brenner Tumor | 1 | 2010 | 1 | 0.090 |
Why?
| | Signal Transduction | 2 | 2021 | 4524 | 0.090 |
Why?
| | Cell Proliferation | 4 | 2021 | 2199 | 0.090 |
Why?
| | Papillomaviridae | 1 | 2010 | 102 | 0.090 |
Why?
| | Ischemia | 1 | 2013 | 362 | 0.090 |
Why?
| | Prostatectomy | 4 | 2013 | 98 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1361 | 0.080 |
Why?
| | Risk Factors | 5 | 2021 | 8637 | 0.080 |
Why?
| | Polymerase Chain Reaction | 2 | 2010 | 995 | 0.080 |
Why?
| | Incidence | 1 | 2015 | 2316 | 0.080 |
Why?
| | Germinoma | 1 | 2007 | 12 | 0.070 |
Why?
| | Receptors, Steroid | 1 | 2007 | 48 | 0.070 |
Why?
| | Endoribonucleases | 1 | 2007 | 62 | 0.070 |
Why?
| | Muscles | 1 | 1988 | 322 | 0.070 |
Why?
| | Models, Anatomic | 2 | 2004 | 87 | 0.070 |
Why?
| | Testicular Neoplasms | 1 | 2007 | 97 | 0.070 |
Why?
| | DNA-Cytosine Methylases | 1 | 2006 | 5 | 0.070 |
Why?
| | Site-Specific DNA-Methyltransferase (Adenine-Specific) | 1 | 2006 | 4 | 0.070 |
Why?
| | Kidney | 1 | 2013 | 1184 | 0.070 |
Why?
| | Prostate-Specific Antigen | 2 | 2018 | 153 | 0.070 |
Why?
| | Histone Acetyltransferases | 1 | 2006 | 51 | 0.070 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2008 | 212 | 0.060 |
Why?
| | Adult | 14 | 2015 | 30604 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2016 | 1897 | 0.060 |
Why?
| | MCF-7 Cells | 2 | 2016 | 105 | 0.060 |
Why?
| | Anilides | 2 | 2016 | 67 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2222 | 0.060 |
Why?
| | Gene Frequency | 1 | 2006 | 481 | 0.060 |
Why?
| | Carcinoma, Lobular | 1 | 2005 | 44 | 0.060 |
Why?
| | Homeodomain Proteins | 1 | 2008 | 464 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2005 | 686 | 0.060 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 447 | 0.060 |
Why?
| | Logistic Models | 2 | 2021 | 1843 | 0.060 |
Why?
| | Uterine Cervical Neoplasms | 1 | 2007 | 217 | 0.060 |
Why?
| | Reactive Nitrogen Species | 1 | 2004 | 21 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2004 | 58 | 0.060 |
Why?
| | Trans-Activators | 1 | 2006 | 368 | 0.060 |
Why?
| | Atrophy | 2 | 2014 | 151 | 0.060 |
Why?
| | Papillomavirus Infections | 1 | 2007 | 262 | 0.060 |
Why?
| | Causality | 1 | 2004 | 105 | 0.060 |
Why?
| | Sensitivity and Specificity | 4 | 2010 | 1700 | 0.050 |
Why?
| | Cyclooxygenase 2 | 1 | 2004 | 164 | 0.050 |
Why?
| | Isoenzymes | 1 | 2004 | 285 | 0.050 |
Why?
| | Carcinoma | 1 | 2003 | 199 | 0.050 |
Why?
| | Odds Ratio | 2 | 2017 | 954 | 0.050 |
Why?
| | DNA Damage | 1 | 2004 | 357 | 0.050 |
Why?
| | Reactive Oxygen Species | 1 | 2004 | 536 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 499 | 0.050 |
Why?
| | Pancreatic Neoplasms | 1 | 2008 | 733 | 0.050 |
Why?
| | Bone and Bones | 1 | 2024 | 278 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 434 | 0.050 |
Why?
| | Neoplasm Metastasis | 2 | 2017 | 530 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1440 | 0.050 |
Why?
| | Autopsy | 2 | 2013 | 85 | 0.040 |
Why?
| | Androgens | 1 | 2021 | 167 | 0.040 |
Why?
| | T-Lymphocytes | 1 | 2007 | 1749 | 0.040 |
Why?
| | Statistics as Topic | 1 | 2000 | 294 | 0.040 |
Why?
| | Cell Nucleus | 2 | 2016 | 554 | 0.040 |
Why?
| | Physician Assistants | 1 | 2000 | 66 | 0.040 |
Why?
| | Cats | 2 | 1990 | 205 | 0.040 |
Why?
| | Nurse Practitioners | 1 | 2000 | 102 | 0.040 |
Why?
| | Filamins | 1 | 2019 | 19 | 0.040 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 12 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2004 | 1134 | 0.040 |
Why?
| | Electric Stimulation | 2 | 1990 | 261 | 0.040 |
Why?
| | Mice | 3 | 2024 | 14935 | 0.040 |
Why?
| | Molecular Imaging | 1 | 2019 | 50 | 0.040 |
Why?
| | Gene Expression Profiling | 1 | 2005 | 1523 | 0.040 |
Why?
| | Cell Cycle | 1 | 2021 | 544 | 0.040 |
Why?
| | Isometric Contraction | 2 | 1990 | 154 | 0.040 |
Why?
| | Kynurenine | 1 | 2018 | 80 | 0.040 |
Why?
| | Membrane Proteins | 1 | 2004 | 1022 | 0.040 |
Why?
| | Pathologists | 1 | 2017 | 15 | 0.040 |
Why?
| | Animals | 5 | 2024 | 31837 | 0.040 |
Why?
| | Tissue Array Analysis | 2 | 2008 | 50 | 0.040 |
Why?
| | Insulin-Like Growth Factor Binding Protein 2 | 1 | 2017 | 9 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2019 | 348 | 0.040 |
Why?
| | Everolimus | 1 | 2017 | 61 | 0.040 |
Why?
| | Trastuzumab | 1 | 2017 | 89 | 0.030 |
Why?
| | DNA, Viral | 2 | 2010 | 350 | 0.030 |
Why?
| | Cyclohexanes | 1 | 2016 | 22 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2000 | 1081 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2019 | 413 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2000 | 490 | 0.030 |
Why?
| | Cytokines | 1 | 2004 | 1843 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 476 | 0.030 |
Why?
| | Oncogenes | 1 | 2016 | 108 | 0.030 |
Why?
| | Gene Expression | 1 | 2020 | 1422 | 0.030 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2016 | 180 | 0.030 |
Why?
| | Computer Simulation | 2 | 2013 | 880 | 0.030 |
Why?
| | Sex Factors | 1 | 2000 | 1721 | 0.030 |
Why?
| | Receptors, Progesterone | 2 | 2007 | 319 | 0.030 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2017 | 286 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 706 | 0.030 |
Why?
| | Tosyl Compounds | 1 | 2014 | 14 | 0.030 |
Why?
| | Neoplasm Grading | 1 | 2015 | 243 | 0.030 |
Why?
| | Blotting, Western | 2 | 2007 | 1151 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2013 | 2769 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2014 | 183 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2014 | 232 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2019 | 480 | 0.030 |
Why?
| | Estradiol | 1 | 2016 | 455 | 0.030 |
Why?
| | Binding Sites | 1 | 2016 | 1176 | 0.030 |
Why?
| | Predictive Value of Tests | 2 | 2008 | 1801 | 0.030 |
Why?
| | Calcium | 1 | 2019 | 1104 | 0.030 |
Why?
| | Cystatin C | 1 | 2013 | 62 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2014 | 623 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2013 | 224 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 9105 | 0.020 |
Why?
| | Creatinine | 1 | 2013 | 424 | 0.020 |
Why?
| | Neurons | 1 | 2019 | 1282 | 0.020 |
Why?
| | Nerve Endings | 1 | 1990 | 5 | 0.020 |
Why?
| | Colorado | 1 | 2000 | 4089 | 0.020 |
Why?
| | Histocytochemistry | 1 | 1990 | 79 | 0.020 |
Why?
| | Reperfusion Injury | 1 | 2013 | 254 | 0.020 |
Why?
| | CA-125 Antigen | 1 | 2010 | 12 | 0.020 |
Why?
| | Carcinoembryonic Antigen | 1 | 2010 | 37 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2000 | 4406 | 0.020 |
Why?
| | Mutation | 1 | 2020 | 3353 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2014 | 1663 | 0.020 |
Why?
| | Prospective Studies | 2 | 2013 | 6218 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2000 | 4634 | 0.020 |
Why?
| | Zinc Finger E-box-Binding Homeobox 1 | 1 | 2008 | 23 | 0.020 |
Why?
| | Up-Regulation | 1 | 2011 | 812 | 0.020 |
Why?
| | Spinal Nerve Roots | 1 | 1988 | 28 | 0.020 |
Why?
| | Tissue Fixation | 1 | 2008 | 27 | 0.020 |
Why?
| | Octamer Transcription Factor-3 | 1 | 2007 | 16 | 0.020 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2007 | 49 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2008 | 64 | 0.020 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 195 | 0.020 |
Why?
| | CD3 Complex | 1 | 2007 | 92 | 0.020 |
Why?
| | Transcription Factor AP-2 | 1 | 2007 | 81 | 0.020 |
Why?
| | Hysterectomy | 1 | 2008 | 106 | 0.020 |
Why?
| | Gene Silencing | 1 | 2008 | 172 | 0.020 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 82 | 0.020 |
Why?
| | Papanicolaou Test | 1 | 2007 | 39 | 0.020 |
Why?
| | Adolescent | 2 | 2007 | 17826 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2011 | 1355 | 0.020 |
Why?
| | Vaginal Smears | 1 | 2007 | 50 | 0.020 |
Why?
| | Organ Size | 1 | 2008 | 435 | 0.020 |
Why?
| | Cadherins | 1 | 2008 | 176 | 0.020 |
Why?
| | Nuclear Receptor Coactivator 3 | 1 | 2006 | 6 | 0.020 |
Why?
| | Alphapapillomavirus | 1 | 2007 | 36 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2007 | 297 | 0.020 |
Why?
| | Endosonography | 1 | 2008 | 140 | 0.020 |
Why?
| | Acute Kidney Injury | 1 | 2013 | 638 | 0.020 |
Why?
| | Adenocarcinoma, Clear Cell | 1 | 2005 | 14 | 0.020 |
Why?
| | Preoperative Care | 1 | 2008 | 317 | 0.020 |
Why?
| | Pancreas | 1 | 2008 | 277 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2006 | 338 | 0.020 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2005 | 44 | 0.020 |
Why?
| | Adenocarcinoma, Mucinous | 1 | 2005 | 61 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2008 | 611 | 0.020 |
Why?
| | Postmenopause | 1 | 2006 | 303 | 0.010 |
Why?
| | Breast | 1 | 2005 | 141 | 0.010 |
Why?
| | Ultrasonography | 1 | 2007 | 633 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 3897 | 0.010 |
Why?
| | Pilot Projects | 1 | 2008 | 1372 | 0.010 |
Why?
| | Neoadjuvant Therapy | 1 | 2005 | 305 | 0.010 |
Why?
| | Mitochondria | 1 | 2008 | 751 | 0.010 |
Why?
| | Time Factors | 1 | 2013 | 6125 | 0.010 |
Why?
| | Genetic Variation | 1 | 2007 | 876 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2007 | 1270 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2008 | 2558 | 0.010 |
Why?
| | Young Adult | 1 | 2015 | 10476 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2007 | 4427 | 0.010 |
Why?
| | Neoplasms | 1 | 2007 | 2106 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2008 | 12543 | 0.010 |
Why?
|
|
Torkko's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|